Status:
UNKNOWN
COVID-19 and Cancer Patients
Lead Sponsor:
Imperial College London
Conditions:
Cancer
Sars-CoV2
Eligibility:
All Genders
18+ years
Brief Summary
Routinely collected data will be used to assess the morbidity and mortality of cancer patients following a positive COVID-19 infection.
Detailed Description
The SARS-CoV-2, (COVID-19) virus of the coronavirus family is believed to have been transmitted from animal to human. On 12th March 2020, the World Health Organisation (WHO) declared this particular c...
Eligibility Criteria
Inclusion
- The investigators will evaluate and include consecutive patients observed in the outpatients and inpatients facility of the study centre meeting all the following CRITERIA:
- Be ≥18 years of age.
- Have a confirmed diagnosis of malignancy of any type.
- Have a confirmed diagnosis of SARS-CoV-2 infection.
Exclusion
- Patients will not be entered in the study database when one or more of the following CRITERIA are present:
- Unconfirmed diagnosis of SARS-CoV-2 infection
- Insufficient clinical/follow up data.
Key Trial Info
Start Date :
March 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 24 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04393974
Start Date
March 24 2020
End Date
March 24 2024
Last Update
July 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Healthcare NHS Trust
London, United Kingdom, W12 0HS